New Drugs Yield Limited Benefit; Big Jump in Drug Prices; AI Boost for Mammo Results

(MedPage Today) -- Two-thirds of cancer drugs approved by the European Medicines Agency from 1995 to 2020 had little or no supporting evidence of added clinical benefit, particularly drugs that had fast-track designation. (The BMJ) Meanwhile...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news